Evaluating Clinical Trial Data and Real-World Evidence of Bispecific Antibodies in Multiple Myeloma

EP: 1.Unmet Needs and Emerging Therapeutic Advances in Multiple Myeloma

EP: 2.Challenges in the Management of Relapsed/Refractory Multiple Myeloma

EP: 3.Addressing Therapeutic Gaps in Multiple Myeloma with Bispecific Antibody Therapies

EP: 4.Bispecific Antibodies in Multiple Myeloma and Practical Definitions of Lines of Therapy

EP: 5.Mechanisms of Action of Bispecific Antibodies in Multiple Myeloma

Now Viewing

EP: 6.Evaluating Clinical Trial Data and Real-World Evidence of Bispecific Antibodies in Multiple Myeloma

In this episode, experts review key clinical trial findings for bispecific antibodies and how these results compare with emerging real world evidence. Panelists explain that early phase studies of BCMA and GPRC5D directed bispecifics demonstrated unprecedented efficacy in heavily pretreated patients, leading to rapid regulatory approvals. They note that response rates across agents consistently fall between 60% and 70%, prompting ongoing investigation into combination strategies intended to improve depth and duration of benefit. Experts also emphasize the need to balance enhanced efficacy with the added toxicities that may arise when bispecifics are paired with other therapies. Real world evidence is described as an important complement to trial data because it provides insight into how these agents perform in frail or trial-ineligible populations. Panelists highlight rural cohorts showing comparable response rates, reinforcing confidence that bispecific antibodies can be effective and safe outside controlle